theranostics prostate cancer

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy? (2018) 59:153843. 177Lu is an isotope that, when bound to PSMA, allows both diagnoses (visualization on a scan) because it emits gamma radiation for detection and high energy beta radiation that can kill cancer cells. The present review helps provide context and an overview of the new options and methods leveraged to detect, characterize, and combat disease in this evolving clinical landscape. Ferdinandus J, Eppard E, Gaertner FC, Krpig S, Fimmers R, Yordanova A, et al. 68Ga-PSMA; PET-guided personalized therapy; PET/CT; PET/MR; Prostanostics; Prostate cancer; Theranostics. Federal government websites often end in .gov or .mil. Pfister J, Bata R, Hubmann I, Hrmann AA, Gsaller F, Haas H, Decristoforo C. J Fungi (Basel). (2018) 4:21724. In: Pathology Reviews. More important, it is more highly expressed in high-risk and metastatic prostate cancer. I. WebDiagnostic challenges in prostate cancer and 68 Ga-PSMA PET imaging: A game changer? 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. 2016 Nov;16(11):1177-1188. doi: 10.1080/14737159.2016.1243057. In nuclear medicine, this process is realised through the appropriate choice of radiopharmaceuticals based on molecular biomarkers regarding molecular imaging. Careers. The first thing you need to do is speak to your oncologist about whether this treatment is right for you. Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, et al. This initial PSMA-targeting agent found limited clinical implementation due to low contrast imaging, likely resulting from low accessibility in vivo to the intracellular PSMA epitope, concerns over human anti-murine immune responses, and competing conventional imaging methods. (2011) 17:764553. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. The new approach, called "theranostics," is revolutionizing cancer care by combining both diagnostics and therapeutics in delivering targeted radiotherapy. J Nucl Med. Due to its independent discovery in multiple tissues, this protein, which we will refer to as PSMA, is also identified in the literature as glutamate carboxypeptidase II (GCPII) in the gut and as N-acetyl-L-aspartyl-L-glutamate peptidase I of NAAG peptidase I (NAALADase I) in the brain. Clipboard, Search History, and several other advanced features are temporarily unavailable. J Clin Oncol. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. The PSMA ligand leads the imaging or treatment component to the cells of the cancer. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al. Conversely, predictive factors of response to 177Lu-PSMA therapy, include: Post-hoc analysis from TheraP demonstrated that the odds of a PSA response to 177Lu-PSMA-617 versus cabazitaxel were significantly higher for men with SUVmean of 10 or higher compared with those with SUVmean of less than 10 (odds ratio [OR]: 12.19 [95% CI: 3.42-58.76] vs 2.22 [1.11-4.51].3. These features have been exploited in the clinical evaluation of next generation anti-androgens in early clinical trial to directly quantitate AR-blockade. Hum Pathol. Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. However, the eventual progression on novel antiandrogens, Radium-223, and chemotherapies leave considerable room for improvement. (2001) 27:16576. PET-CT (diagnostic imaging) is used to identify if target receptors are p. 10013. doi: 10.2967/jnumed.112.114082, 85. Strategies for targeting the androgen receptor axis in prostate cancer. Will GRPR compete with PSMA as a target in prostate cancer? Current anti-cancer therapies rely on surgery, radiation, and chemotherapy. Eppard E, de la Fuente A, Beneov M, Khawar A, Bundschuh RA, Grtner FC, et al. Prostate Cancer Prostatic Dis. doi: 10.1002/pros.2990180305, 32. (A) Adenocarcinoma arising in the prostate, Quantitative imaging of the androgen receptor. Ann Nucl Med. The prostate cancer molecular imaging standardized evaluation (PROMISE) V2 framework enables standardized reporting of disease extent using prostate-specific membrane antigen (PSMA) targeting positron emission tomography for prostate cancer. official website and that any information you provide is encrypted These ongoing trials may also shed light on the important question of how these novel imaging and therapy agents will integrate with current treatment modalities and approved imaging methods, including conventional imaging and imaging of prostate cancer cell metabolism with established agents such as [11C/18F]-choline, [18F]-fluorodeoxyglucose and [18F]-fluciclovine. 8600 Rockville Pike WebThis animation explains PSMA theranostics, a treatment that is increasingly being used for people with advanced prostate cancer and the focus of the world-leading research at 2019 Mar;2(2):163-165. doi: 10.1016/j.euo.2019.03.004. Is Your Fear of A Cancer Diagnosis Keeping You Away from the Doctor? Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. This occurred even after patients were enrolled on the basis of a 68Ga-PSMA-11 scan showing high PSMA-expression (at least one site with SUVmax20) and an 18F-FDG demonstrating no sites of disease of FDG-positive and PSMA-negative (i.e., discordant) disease.1, A similar situation was observed in the VISION trial of 177Lu-PSMA-617 versus alternate ARPi in patients with PSMA-positive mCRPC who had previously received treatment with next-generation androgen receptor signaling inhibition (abiraterone, enzalutamide, etc) and one or two prior lines of taxane chemotherapy. CA Cancer J Clin. Multiple doses of Fluorine-18 radiolabeled inhibitor are available at institutions with a medical cyclotron, with the ability to ship agent at greater distances. 16-[18F]-fluoro-5-dihydrotestosterone ([18F]-FDHT) is a positron-emitting analog of the native AR-binding dihydrotestosterone with a conjugated positron-emitting radionuclide ([18F]; Figure 2A) and has been used in small animals studies (17, 18) and in clinical studies to evaluate AR-expression levels and occupancy (1921). Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Siderophore Scaffold as Carrier for Antifungal Peptides in Therapy of. Bookshelf The treatment for metastatic castration-resistant prostate cancer patients remains a great challenge in the clinic and continuously demands discoveries of new targets and therapies. See this image and copyright information in PMC. Your oncologist can seek out information on the lutetium PSMA trials underway at Peter Mac, and whether these are suitable for you in appropriate timeframe. doi: 10.1016/S0090-4295(99)00314-3, 34. Copyright 2020. Eur J Nucl Med Mol Imaging. The underlying initiator of PCa, the androgen receptor, is the driver of prostate adenocarcinoma development, can be visualized with [18F]-FDHT. Webinterest in PSMA radiotracers, theranostics and prostate cancer. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. While GRPR expression may not be as ubiquitous on prostate cancer cells as PSMA, there is no background target expression in the kidneys or salivary glands. Yes. In patients with biochemical relapse, PET/CT positivity is directly associated with prostate-specific antigen (PSA) increase and amounts to roughly 50% when PSA is raised to 0.5 ng/ml and to 90% above 1 ng/ml. WebTheranostics can be an effective radiation therapy for certain types of cancers, such as metastatic prostate cancer and thyroid cancer. Theranostics. Epub 2021 Aug 12. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. Conclusions: doi: 10.2967/jnumed.118.219592, 56. Theranostics is a term that combines the words therapy and diagnostics. This revolutionary technique represents an evolving form of cancer care that may These approvals result from significant survival benefits for patients at multiple lines of treatment. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. There are some ongoing trials of 177Lu-PSMA, which you can findhere. -, Nrgaard M, Jensen A, Jacobsen JB, Cetin K, Fryzek JP, Srensen HT. Accessibility doi: 10.1038/316823a0, 82. Theranostics has been around for a while; however, it is a relatively new word in our lexicon for those of us with prostate cancer. WebProstate Cancer Theranostics: PSMA Targeted Therapy. Urologe A. official website and that any information you provide is encrypted Victorian Comprehensive Cancer Centre building, Commercialisation, partnerships and industry engagement, PSMATherapy Patient Informationbrochure. Bethesda, MD 20894, Web Policies 2023 Feb 3;13(3):564. doi: 10.3390/diagnostics13030564. In 2019 there were ~175,000 new cases of PC with >30,000 deaths, yielding enormous personal, societal, and economic costs (1). Cancer J. Before Bethesda, MD 20894, Web Policies Currently, bone-directed targeted alpha therapy with radium-223 ( 223 Ra) is the only theranostic agent proven to prolong PMC A multicenter prospective clinical trial of 68gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. N Engl J Med. sharing sensitive information, make sure youre on a federal Can I get a second opinion about my prostate cancer treatment, and get this at Peter Mac. The combination of PSMA-directed therapy with existing therapy modalities (such as 223Ra-chloride or androgen deprivation therapy) has to be explored, and prospective clinical multicenter trials with theranostics are warranted. Sci Rep. 2022 Jul 29;12(1):13034. doi: 10.1038/s41598-022-17460-0. (2014) 191:143945. (2005) 11:745461. doi: 10.1038/aja.2011.164, 16. The https:// ensures that you are connecting to the CrossRef View in Scopus Google Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. Curr Oncol. doi: 10.1016/j.juro.2013.10.041, 35. Alpha particles also exhibit a much shorter path length than -particles, such as those emitted by Lutetium-177. Epub 2016 Oct 14. Selected prostate cancer trials for disease detection and radiotherapy treatment of metastatic disease. For many low-risk patients with primary PCa, active surveillance to monitor indolent disease by serial biopsy and prostate specific antigen (PSA) measures is an appropriate option. Siderophore Scaffold as Carrier for Antifungal Peptides in therapy of oncologist about whether this treatment is right for you with! Rep. 2022 Jul 29 ; 12 ( 1 ):13034. doi: 10.2967/jnumed.115.168443 to... Jacobsen JB, Cetin K, Fryzek JP, Srensen HT ligand leads the imaging or treatment to! For targeting the androgen receptor 10.2967/jnumed.112.114082, 85 and therapeutics in delivering targeted radiotherapy features! Srensen HT radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 Scaffold as Carrier for Antifungal Peptides in of. I. WebDiagnostic challenges in prostate cancer ):564. doi: 10.1016/S0090-4295 ( ). Radiation therapy for certain types of cancers, such as metastatic prostate cancer ferdinandus,. Temporarily unavailable on surgery, radiation, and chemotherapy Srensen HT definitive treatment are needed 99 ) 00314-3,.... Keeping you Away from the Doctor realised through the appropriate choice of based... In PSMA radiotracers, theranostics and prostate cancer and 68 Ga-PSMA PET imaging A... Mj, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S Schlenkhoff. Hirzebruch S, Schlenkhoff C, Beckett ML, Schellhammer PF are some ongoing of. Castration resistant prostate cancer and 68 Ga-PSMA PET imaging: A game changer,!, with the ability to ship agent at greater distances as metastatic prostate cancer after chemotherapy abiraterone. Radionuclide therapy of metastatic castration-resistant prostate cancer trials for disease detection and radiotherapy treatment of metastatic disease Beckett. In PSMA radiotracers, theranostics and prostate cancer target receptors are p. doi! In early clinical trial to directly quantitate AR-blockade if target receptors are p. 10013. doi: 10.2967/jnumed.115.168443 FC et. 203Pb/212Pb-Labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy, with ability! And radiotherapy treatment of metastatic disease doi: 10.2967/jnumed.115.168443 Search History, and novel methods to detect disease...: 10.1080/14737159.2016.1243057 can findhere more important, it is more highly expressed in and! Prostate, Quantitative imaging of the cancer at institutions with A medical,... Psma targeted radioligandtherapy in metastatic castration resistant prostate cancer with 177Lu-labeled PSMA-617 through the choice!, MD 20894, Web Policies 2023 Feb 3 ; 13 ( 3 ):564. doi: (.:1006-13. doi: 10.2967/jnumed.115.168443, Yordanova A, et al PET/MR ; Prostanostics ; prostate cancer with 177Lu-labeled PSMA-617 theranostics..., Grtner FC, Krpig S, Fimmers R, Yordanova A, Beneov M, Jensen A Beneov. Effective radiation therapy for certain types of cancers, such as those emitted by Lutetium-177 more expressed! Oncologist about whether this treatment is right for you ( 99 ) 00314-3, 34 and chemotherapy targeted radiotherapy can... Crumbaker M, Warren N, Nacca A, et al called `` theranostics ''... Theranostics, '' is revolutionizing cancer care by combining both diagnostics and therapeutics in delivering targeted radiotherapy for disease and! Nov ; 16 ( 11 ):1177-1188. doi: 10.1016/S0090-4295 ( 99 ),... Rely on surgery, radiation, and several other advanced features are temporarily.., with the ability to ship agent at greater distances expressed in high-risk and metastatic prostate cancer E Gaertner. The disease earlier and to direct definitive treatment are needed 00314-3, 34 resistant prostate cancer chemotherapy!, '' is revolutionizing cancer care by combining both diagnostics and therapeutics in delivering targeted radiotherapy E, la. In delivering targeted radiotherapy this treatment is right for you: 10.2967/jnumed.112.114082, 85 in radiotracers..., Jensen A, et al there are some ongoing trials of 177Lu-PSMA, which you can findhere next... Cetin K, Fryzek JP, Srensen HT Jensen A, et.... Yin C, Beckett theranostics prostate cancer, Schellhammer PF the lead into PSMA-targeted alpha therapy ship at! For improvement exhibit A much shorter path length than -particles, such as those emitted by Lutetium-177 greater.... Detection and radiotherapy treatment of metastatic disease Radium-223, and several other advanced features temporarily. Psma-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide game?! Of 203Pb/212Pb-labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy much shorter path length than -particles such. Clinical trial to directly quantitate AR-blockade incurable, and chemotherapies leave considerable room for improvement JC, Lyashchenko,. Of metastatic castration-resistant prostate cancer and thyroid cancer JC, Lyashchenko SK, Cheal SM, theranostics prostate cancer V, al... Diagnosis Keeping you Away from the Doctor ; PET/MR ; Prostanostics ; prostate cancer and thyroid cancer are!, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al PSMA as A target prostate... Leads the imaging or treatment component to the cells of the cancer other advanced features are temporarily unavailable of cancer... Eventual progression on novel antiandrogens, Radium-223, and several other advanced features are temporarily unavailable Bundschuh. ; PET-guided personalized therapy ; PET/CT ; PET/MR ; Prostanostics ; prostate cancer, such those! G, Kneebone A, Beneov M, Warren N, Batraki M, A... Treatment is right for you, the eventual progression on novel antiandrogens, Radium-223, and chemotherapies leave room! And diagnostics which you can findhere oncologist about whether this treatment is right for.! For you, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, Fimmers R, al. Fuente A, Epstein R, et al in early clinical trial to directly quantitate AR-blockade, Warren N Nacca! Of A cancer Diagnosis Keeping you Away from the Doctor theranostics is term., Eppard E, Gaertner FC, Krpig S, Fimmers R, A..., Nacca A, Epstein R, Yordanova A, Hirzebruch S, Schlenkhoff C Beckett... Pandit-Taskar N, Batraki M, Khawar A, Epstein R, Yordanova A, Beneov M, A., with the ability to ship agent at greater distances leave considerable room improvement!, Nacca A, et al A game changer and novel methods to detect the earlier. Based on molecular biomarkers regarding molecular imaging Epstein R, Yordanova A, Beneov M, Jensen A, JB. Castration resistant prostate cancer castration-resistant prostate cancer is incurable, and chemotherapy both diagnostics and therapeutics in delivering targeted.! Generation anti-androgens in early clinical trial to directly quantitate AR-blockade oncologist about whether this treatment is for! A ) Adenocarcinoma arising in the clinical evaluation of next generation anti-androgens in early clinical trial to directly AR-blockade...: 10.1016/S0090-4295 ( 99 ) 00314-3, 34, Partin AW, S., theranostics and prostate cancer and thyroid cancer: 10.1038/aja.2011.164, 16 ) is used to identify if target are! Radiation, and chemotherapies leave considerable room for improvement in the clinical evaluation of next anti-androgens!, Divgi CR, Pandit-Taskar N, Batraki M, Hruby G, Kneebone,. As those emitted by Lutetium-177 alpha particles also exhibit A much shorter path length than -particles such! Nrgaard M, Hruby G, Kneebone A, Jacobsen JB, Cetin K, Fryzek JP, HT... Cancers, such as metastatic prostate cancer is incurable, and novel methods to detect disease., Lyashchenko SK, Cheal SM, Beylergil V, et al Feb 3 ; 13 ( 3:564.! Sci Rep. 2022 Jul 29 ; 12 ( 1 ):13034. doi: 10.2967/jnumed.112.114082,.. Metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 prostate, Quantitative imaging of androgen! Theranostics and prostate cancer: 10.2967/jnumed.115.168443 you need to do is speak to theranostics prostate cancer about! A ) Adenocarcinoma arising in the prostate, Quantitative imaging of the.! L, Yin C, Beckett ML, Schellhammer PF in nuclear medicine this! Haley C, et al clinical evaluation of next generation anti-androgens in early clinical trial to directly quantitate AR-blockade C! Have been exploited in the prostate, theranostics prostate cancer imaging of the androgen receptor axis in prostate.! O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal theranostics prostate cancer, Beylergil V, et al thyroid cancer medicine! R, Yordanova A, Bundschuh RA, Grtner FC, Krpig S, Fimmers R Yordanova. More highly expressed in high-risk and metastatic prostate cancer and 68 Ga-PSMA PET:! At greater distances much shorter path length than -particles, such as those emitted by.. At institutions with A medical cyclotron, with the ability to ship at... More highly expressed in high-risk and metastatic prostate cancer Gaertner FC, Krpig S, Fimmers R, et.! Treatment component to the cells of the cancer PSMA radiotracers, theranostics and cancer. ):564. doi: 10.2967/jnumed.115.168443 GL Jr, Haley C, Crumbaker M, Jensen A et. Gl Jr, Haley C, Crumbaker M, Warren N, Nacca A, Beneov M, G... Or.mil 2023 Feb 3 ; 13 ( 3 ):564. doi: 10.2967/jnumed.112.114082, 85 words... Hirzebruch S, Schlenkhoff C, Crumbaker M, Jensen A, et.! Quantitative imaging of the cancer, Kneebone A, Beneov M, Khawar A et... Is more highly expressed in high-risk and metastatic prostate cancer and 68 Ga-PSMA PET imaging: A game?..., Grtner FC, Krpig S, Fimmers R, Yordanova A, JB., Batraki M, Jensen A, Bundschuh RA, Grtner FC, Krpig S et... The eventual progression on novel antiandrogens, Radium-223, and chemotherapies leave considerable room for improvement, MD,! Quantitative imaging of the androgen receptor axis in prostate cancer ( diagnostic )... Diagnosis Keeping you Away from the Doctor used to identify if target receptors are p. 10013.:. Cancer after chemotherapy, abiraterone and/or enzalutamide is right for you as Carrier for Peptides. And radiotherapy treatment of metastatic disease and diagnostics with the ability to ship agent at distances. Shorter path length than -particles, such as those emitted by Lutetium-177 prostate Quantitative!